[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342219-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342219-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pd-l2-act-as-an-independent-immune-checkpoint-in-colorectal-cancer-beyond-pd-l1","PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1","","Immune checkpoint blockade offers therapeutic potential for colorectal cancer by enabling the patient immune system to attack malignant cells, yet many patients show limited responses and resistance mechanisms remain incompletely defined. This study uses syngeneic mouse models and MC38 cells to evaluate PD-L2 in the tumor microenvironment and compares it to the PD-1/PD-L1 axis. The findings identify PD-L2 as a complementary, spatially distinct checkpoint linked to immune-cell infiltration and antigen presentation, supporting enhanced antitumor immunity beyond PD-L1.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pd-l2-act-as-an-independent-immune-checkpoint-in-colorectal-cancer-beyond-pd-l1/342219/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pd-l2-act-as-an-independent-immune-checkpoint-in-colorectal-cancer-beyond-pd-l1/342219.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central goal of this study in colorectal cancer immunotherapy?","Question",{"text":63,"@type":64},"To determine whether PD-L2 functions as an independent immune checkpoint and whether targeting PD-L2 can complement PD-1/PD-L1 blockade in colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the experiments conducted to test PD-L2’s role?",{"text":68,"@type":64},"Experiments used C57BL/6 mice with syngeneic MC38 cell line models, along with qPCR, Western blot, and flow cytometry, plus bioinformatics for clinical survival analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What key findings relate PD-L2 to immune evasion and antitumor immunity?",{"text":72,"@type":64},"Targeting PD-L2 is proposed as a complementary strategy; PD-L2 shows unique spatial distribution in the tumor microenvironment and correlates with PD-L1 expression and infiltration of multiple immune cell subtypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342219,1790193142,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 02 December 2024 DOI 10.3389/fimmu.2024.1486888  \nOPEN ACCESS  \nEDITED BY  \nArutha Kulasinghe,  \nThe University of Queensland, Australia  \nREVIEWED BY  \nDr. Samantha Sharma,  \nIndiana University School of Medicine,  \nUnited States Anna Fialov´a, SOTIO a.s., Czechia  \n*CORRESPONDENCE  \nLvyun Zhu  \n [zhulvyun@nudt.edu.cn](zhulvyun@nudt.edu.cn)[ ](zhulvyun@nudt.edu.cn)Tao Hou  \n [houtao@csu.edu.cn](houtao@csu.edu.cn)  \nRECEIVED 27 August 2024  \nACCEPTED 11 November 2024  \nPUBLISHED 02 December 2024  \nCITATION  \nZhu L, Qu Y, Yang J, Shao T, Kuang J, Liu C, Qi Y, Li M, Li Y, Zhang S, Wang J, Liu Y, Liu J, Hu Y, Zhu L and Hou T (2024) PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1 .  \nFront. Immunol. 15:1486888 .  \ndoi: 10.3389/fimmu.2024.1486888  \nCOPYRIGHT  \n© 2024 Zhu, Qu, Yang, Shao, Kuang, Liu, Qi, Li, Li, Zhang, Wang, Liu, Liu, Hu, Zhu and Hou.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1  \nLvyun Zhu 1*, Ying Qu 1, Junru Yang 1, Tong Shao 1, Jingyu Kuang 1, Chuanyang Liu 1, Yanhua Qi 1, Ming Li 1,2, Yingying Li 1, Sujuan Zhang 3, Jingyang Wang 1, Yu Liu 1, Jiali Liu 1, Yanming Hu 3, Lingyun Zhu 1 and Tao Hou 3*  \n1 Department of Biology and Chemistry, College of Sciences, National University of Defense Technology, Changsha, Hunan, China, 2 Laboratory of Liquid Propellant Application Technology, Jiuquan Satellite Launch Centre, Jiuquan, China, 3 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China  \nIntroduction: Immunotherapy, especially immune checkpoint blockade (ICB), holds promise as a therapeutic strategy in colorectal cancer (CRC) by harnessing the patient’s immune system to target malignant cells. Particularly, the PD-1/PDL1 axis is widely recognized for its critical role in tumor microenvironment immunosuppression. Antibodies targeting PD-1 or PD-L1 have shown sustained efﬁcacy against various cancers, including CRC. Nonetheless, many CRC patients exhibit limited responses to such immunotherapy, and the resistance mechanisms remain incompletely understood.  \nMethods: We conducted experiments with C57BL/6 mice, and used the MC38 cell line for ICB treatment studies in syngeneic mouse models. Gene and protein analyses were performed using qPCR, Western Blot, and ﬂow cytometry, with bioinformatics for clinical data survival analysis.  \nResults: In this study, we reveal that targeting PD-L2 emerges as a complementary therapeutic strategy to PD-1/PD-L1 blockade in CRC. Although PD-L2 is also inducible by IFNg, like PD-L1, it displays a unique spatial distribution within the tumor microenvironment, implying discrete roles in immune evasion. Additionally, we uncovered a signiﬁcant correlation between PD-L1 and PD-L2 expression levels and the inﬁltration of various immune cells, encompassing multiple dendritic cell (DC) subtypes. This correlation implies an enhanced antigen presentation process that may be unleashed by blocking these two immune checkpoints.  \nDiscussion: Our results highlight the signiﬁcance of PD-L2 as an essential immune checkpoint alongside PD-L1 and emphasize its potential as a target for bolstering antitumor immunity in colorectal cancer.  \nKEYWORDS  \nimmune checkpoint blockade, colorectal cancer, antitumor immunity, therapeutic target, tumor microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nColorectal cancer (CRC) ranks as the third most common cancer and the seco","cbCaitWrdvAIYiJt","https://ap.wps.com/l/cbCaitWrdvAIYiJt","pdf",11394175,11,"English","# Introduction\n## Immune checkpoint blockade in colorectal cancer\n# Methods\n## Animal and cell model design\n# Results\n## PD-L2 as a complementary checkpoint\n## Correlation with immune infiltration and antigen presentation\n# Discussion\n## PD-L2 targeting for antitumor immunity","[{\"question\":\"What is the central goal of this study in colorectal cancer immunotherapy?\",\"answer\":\"To determine whether PD-L2 functions as an independent immune checkpoint and whether targeting PD-L2 can complement PD-1/PD-L1 blockade in colorectal cancer.\"},{\"question\":\"How were the experiments conducted to test PD-L2’s role?\",\"answer\":\"Experiments used C57BL/6 mice with syngeneic MC38 cell line models, along with qPCR, Western blot, and flow cytometry, plus bioinformatics for clinical survival analysis.\"},{\"question\":\"What key findings relate PD-L2 to immune evasion and antitumor immunity?\",\"answer\":\"Targeting PD-L2 is proposed as a complementary strategy; PD-L2 shows unique spatial distribution in the tumor microenvironment and correlates with PD-L1 expression and infiltration of multiple immune cell subtypes.\"}]","PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1 | PDF",1790045821,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e1116e1e3ea41355f2aa20ccb4fab3f.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08616903e53c6efc29c796a877e34b3d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7872f32269640ae835835cfb12cd2fb4.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/131a89bd6145f4862813d5ee452293f5.webp",980,1385]